Mu Xin, Huang Ou, Jiang Min, Xie Zuoquan, Chen Debo, Zhang Xi
Department of Urology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian 362000, P.R. China.
Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, P.R. China.
Oncol Lett. 2019 Jul;18(1):742-750. doi: 10.3892/ol.2019.10363. Epub 2019 May 17.
The roles of Ephrin B (EphB) receptors in cancer are relatively unknown as these receptors are associated with complex signaling pathways. A limited number of studies have investigated the association between EphB receptors and prognosis. Using the Kaplan-Meier plotter database, the present study investigated the associations between the mRNA expression levels of five EphB receptors and the outcomes of 3,554 patients with breast cancer who had been followed-up for 20 years. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated to assess the relative risk of survival. The results demonstrated that high mRNA expression levels of EphB2 (HR, 0.74; 95% CI, 0.66-0.84; P=2.1×10-6), EphB4 (HR, 0.82; 95% CI, 0.72-0.93; P=0.0023) and EphB6 (HR, 0.69; 95% CI, 0.61-0.78; P=3×10-9) were significantly associated with improved survival, while a high mRNA expression level of EphB3 (HR, 1.14; 95% CI, 1.01-1.28; P=0.029) was associated with worse survival for patients with breast cancer. High expression levels of all EphB receptors, including EphB1 (HR, 1.4; 95% CI, 1.02-1.94; P=0.039), EphB2 (HR, 1.34; 95% CI, 1.07-1.67; P=0.011), EphB3 (HR, 1.39; 95% CI, 1.11-1.73, P=0.0038), EphB4 (HR, 1.33; 95% CI, 1.06-1.67; P=0.013) and EphB6 (HR, 1.32; 95% CI, 1.05-1.65; P=0.016), were associated with an increased risk of mortality in patients with lymph-node-positive breast cancer. High mRNA expression levels of EphB1 were not associated with survival for all patients with breast cancer (HR, 0.85; 95% CI, 0.72-1.01; P=0.058). The results of the present suggested that EphB receptors may be useful as prognostic biomarkers of breast cancer.
Ephrin B（EphB）受体在癌症中的作用相对未知，因为这些受体与复杂的信号通路相关。有限的研究调查了EphB受体与预后之间的关联。本研究使用Kaplan-Meier绘图仪数据库，调查了5种EphB受体的mRNA表达水平与3554例乳腺癌患者随访20年结果之间的关联。计算风险比（HR）和95%置信区间（CI）以评估生存的相对风险。结果表明，EphB2（HR，0.74；95%CI，0.66-0.84；P=2.1×10-6）、EphB4（HR，0.82；95%CI，0.72-0.93；P=0.0023）和EphB6（HR，0.69；95%CI，0.61-0.78；P=3×10-9）的高mRNA表达水平与生存改善显著相关，而EphB3的高mRNA表达水平（HR，1.14；95%CI，1.01-1.28；P=0.029）与乳腺癌患者的较差生存相关。所有EphB受体的高表达水平，包括EphB1（HR，1.4；95%CI，1.02-1.94；P=0.039）、EphB2（HR，1.34；95%CI，1.07-1.67；P=0.011）、EphB3（HR，1.39；95%CI，1.11-1.73，P=0.0038）、EphB4（HR，1.33；95%CI，1.06-1.67；P=0.013）和EphB6（HR，1.32；95%CI，1.05-1.65；P=0.016），与淋巴结阳性乳腺癌患者的死亡风险增加相关。EphB1的高mRNA表达水平与所有乳腺癌患者的生存无关（HR，0.85；95%CI，0.72-1.01；P=0.058）。本研究结果表明，EphB受体可能作为乳腺癌的预后生物标志物。
